IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Eiji MATSUURA

Mail Stop: PCT

Serial No. NEW

Attorney Docket No. 2005 0348A

Filed March 4, 2005

METHOD OF MEASURING OXIDIZED LDL/β2-GLYCOPROTEIN I COMPLEX OCCURRING IN THE LIVING BODY [Corresponding to PCT/JP2003/011388 Filed September 5, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- [X] each U.S. Patent and U.S. Patent application publication;
- [X] each reference previously cited in the international application PCT/JP2003/011388; and/or
- [] each reference previously cited in prior parent application Serial No.
- 1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

The PTO did not receive the following listed item(s) Homs manyed

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office
Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
- 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [X] a foreign patent office search report (in the English language) submitted herewith,
 - c. [] the concise explanation contained in the specification of the present application at page,
 - d. [] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [X] A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Eiji MATSUURA

By

Warren M. Cheek, Jr.

Registration No. 33,367

Attorney for Applicant

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 March 4, 2005

Sheet 1 of 1 INFORMA					TION DISCLOSURE STATEMENT					
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE				ATTY DOCKET NO. 2005_0348A SERIAL NO. 10/526494						
PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Eiji MATSUURA						
(Use several sheets if necessary) Date Submitted to PTO: March 4, 2005				FILING DATE March 4, 2005			GROUP			
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL	ļ	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	AA						_			
	AB		*	!						
	AC									
	AD							 -		
	AE									
	AF							<u>~</u>		
	AG									
	АН									
	AI					-				
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE	C	COUNTRY CLASS SUBCLASS TRANSLATION YES NO			TION NO		
	AJ	× 95/09363	4/1995		wo					
	AK	¥ 7-306202	11/1995		JP					
	AL									
	АМ	<u> </u>								
.,10	AN									
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)										
	AO Koike, "Antiphospholipid antibodies in arterial thrombosis", Annals of Medicine, Vol. 32, No. Supp. 1, 2000, pp. 27-31.									
	AP						-			
	AQ			-			-			
EXAMINER					DATE CONSIDERED					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.